Latest news
Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 17:37:18 GMTCapricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics. - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTFDA expert panel recommends against approval of Capricor’s Duchenne drug - STATSTAT · Wed, 29 Jul 2026 07:00:00 GMTCapricor Duchenne cell therapy voted down by FDA panel - BioPharma DiveBioPharma Dive · Wed, 29 Jul 2026 07:00:00 GMTFDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute - Fierce BiotechFierce Biotech · Wed, 29 Jul 2026 07:00:00 GMTFDA panel votes against Capricor's Duchenne heart disease therapy - ReutersReuters · Wed, 29 Jul 2026 07:00:00 GMT